🤝 RLAY $1.2M Institutional Put-Write — A Desk Willing to Own at $12.60, Below the May Offering Price

📅 June 1, 2026 | 🔥 Unusual Activity Detected

---

🎯 The Quick Take

Someone just sold 5,000 RLAY put contracts for ≈$1.2M in premium on a negotiated block cross — and the breakeven on that trade sits below the price institutional investors paid in a $275M public offering only 12 days ago. Translation: a desk is essentially saying "I'll gladly own Relay Therapeutics at $12.60 — even cheaper than the big boys got it last week." With Breakthrough Therapy status on its lead cancer drug, ≈$917M in cash runway into 2029, and no earnings binary inside the expiry window, the structure tells a quietly bullish story.

---

📊 Company Overview

Relay Therapeutics (NASDAQ: RLAY) is a Cambridge, MA precision-oncology biotech, ≈$2.9B market cap, in the Healthcare → Biotechnology sector.

The company's edge is its proprietary Dynamo platform — instead of designing drugs from static protein snapshots (the old way), Relay models how proteins move to find small-molecule pockets competitors miss. That approach produced its lead asset:

🧬 Zovegalisib (RLY-2608) — a selective PI3Kα inhibitor for PIK3CA-mutant HR+/HER2- breast cancer. It earned FDA Breakthrough Therapy Designation on February 3, 2026, the FDA's clearest stamp of "we want to see this approved." Phase 3 (ReDiscover-2) is underway. And just two weeks ago, zovegalisib posted 60% volumetric response in vascular anomalies at the ISSVA World Congress — opening a second rare-disease franchise for the same drug.

💰 Cash position: $642M at March 31 + ≈$275M public offering priced May 19-20 at $12.00/share = ≈$917M total runway into 2029. The dilution overhang is cleared; the company does not need to raise capital again for years.

---

💰 The Option Flow Breakdown

The Tape (June 1, 2026 @ 13:38:30 ET):

Order type confirmed: STO (Sell to Open) — new short put position.

📌 Prior open interest was just 10 contracts. Volume came in at 5,000 — meaning ≈5,000 NEW short puts were written in one print. The open is largely confirmed by the volume-to-OI ratio alone.

📌 No cancellations were found on the tape for this contract and date.

---

✅ OI UPDATE (2026-06-02) — STO CONFIRMED

Last updated: 2026-06-02 — open/close confirmed by next-day OPRA OI.

The RLAY $15 July-17 put open interest rose exactly +5,000 — matching today's STO size to the contract. Clean confirmed put-write open. The bullish-leaning institutional accumulation thesis ($12.60 net entry below the May 20 $12 secondary clearing price) stands as written; the desk is now on the books for 5,000 contracts ≈ 500,000-share willingness through Jefferies Healthcare (June 3), Goldman Healthcare (June 8), and the rest of the catalyst window into July-17 expiry.

---

🤓 What This Actually Means — Plain English

Real talk — this is a short put write, and it is NOT a bearish trade. Let me break it down simply.

What "selling a put" actually does:

When you sell a put, you collect cash upfront (the "premium") and take on an obligation: if the stock falls below the strike price at expiration, you get assigned 100 shares per contract at that strike price. Essentially, you're saying: "I'll buy this stock at $15 if the market forces me to — and I already got paid $2.40 per share for making that promise."

For this specific trade:

• 💵 Premium collected: $2.40 per share × 5,000 contracts × 100 shares = $1.2M cash received upfront
• 🎯 Breakeven for the put seller: $15 strike − $2.40 premium = $12.60 net cost basis
• 📍 Where $12.60 lands: That is below the $12.00 clearing price of the May 19-20 public offering — meaning this desk is willing to be assigned RLAY at an effective price better than what institutional allocations paid just 12 trading days ago.
• 📈 Max profit: $1.2M — if RLAY closes above $15 on July 17, 2026, every cent of premium is kept and no shares change hands.
• ⚠️ Max loss (theoretical): If RLAY went to $0, the seller would own 500,000 shares at $15 with $2.40 in offsetting premium — a maximum loss of ≈$6.3M. That does not happen in practice for a clinical-stage biotech with ≈$917M cash, but it's the correct framing.

Why does a desk do this?

Think of it like this: an institution missed the $12 offering (or decided not to participate). Now the stock has recovered to $13.54. Rather than chasing it higher, they sell the $15 put — collecting ≈$2.40 — and essentially tell the market: "Put me in at $12.60 net if RLAY fades back. If it runs to $15+, I'll keep the premium as consolation." It is a bullish-leaning income trade and a discounted stock-accumulation strategy rolled into one.

What a 🤝 BLOCK CROSS means:

This trade printed with OPRA condition code 127 — a single-leg cross. A single broker matched a buyer (the put buyer who is now long the put and paying $1.2M) and a seller (the put writer we're discussing) and crossed the block off the open order book at a negotiated price. There is a known counterparty on the other side who took the opposite bet. This is deliberate institutional positioning, not someone aggressively sweeping offers in the open market. Read it as a calculated, negotiated transaction between two institutional parties who already agreed on price — not panic or urgency.

---

📈 Technical Setup / Chart Check-Up

YTD Performance

RLAY absorbed a ≈9% dilution event on May 19-20 (the $12.00 follow-on offering) and has already recovered to $13.54. That bounce-back from the offering price is meaningful — institutional demand absorbed the new shares, and the stock did not stay pinned near $12. The YTD chart reflects a clinical-stage biotech name in accumulation mode following a major capital raise.

---

Gamma-Based Support & Resistance

Based on the current gamma exposure data (spot ≈$14.03 at time of analysis):

🔵 Support Levels (Put Gamma Below Price):

• $13.00 — total GEX 1.13 (net call-gamma positive at 1.07; strongest nearby anchor below current price)
• $12.00 — total GEX 0.69, net put-gamma −0.64 (meaningful put gamma here; aligns with the May offering clearing price — a historically watched level for institutional re-entry)
• $11.00 — total GEX 0.11 (lighter support; a break below $12 would be a red flag for the trade thesis)
• $10.00 — total GEX 0.87 (net near-flat; deep floor)

🟠 Resistance Levels (Call Gamma Above Price):

• $15.00 — total GEX 1.22 (the STRIKE in our trade; call gamma 1.09 vs put gamma 0.13; this is the key level the put writer wants RLAY to close above by July 17)
• $16.00 — total GEX 0.38 (moderate resistance)
• $17.00 — total GEX 0.88 (next major ceiling; aligns with analyst price target laddering)

What this means for traders:

The $13 gamma level is RLAY's nearest meaningful floor — call gamma dominates there, which means market makers will naturally support the stock around that zone. The $15 strike is the largest single gamma node above current price, making it a natural magnet for price action heading into the July 17 OPEX. The net GEX picture is slightly bullish overall (more call gamma than put gamma at the immediate levels), which supports a gradual drift higher toward $15 as a base case.

The put-write breakeven at $12.60 sits comfortably between the $12 put-heavy zone (strong structural support, the May offering cleared here) and current price. That is a deliberate structural choice.

---

Implied Move Analysis

Options traders are pricing in substantial volatility for this clinical-stage biotech:

Translation for regular folks:

The market is pricing a ±$6.67 move (≈47.5%) by July 17 — RLAY could be anywhere between $7.37 and $20.71 at expiration. For a small/mid-cap biotech in Phase 3, that is actually reasonable. This is the rich implied volatility environment that makes the short put attractive from an income standpoint — the $2.40 premium the desk collected is reflecting that elevated IV.

👀 The put-write breakeven at $12.60 sits meaningfully inside the lower range ($7.37). The put writer is NOT protected against a catastrophic clinical setback that sends the stock near the lower implied move — that is the tail risk of this trade. But the desk is betting the ≈$917M cash runway + Breakthrough Therapy momentum keeps RLAY above $12.60 through July 17.

---

🎪 Catalysts

🔥 Upcoming (Inside the July 17, 2026 Expiry Window)

🗓️ ASCO 2026 Read-Through (now through ≈June 15) — ASCO Annual Meeting ran May 29 – June 2, 2026 in Chicago. Even without a specific RLAY abstract, the entire PI3Kα / breast-cancer competitive landscape gets re-calibrated at ASCO — any new Inavolisib (Roche/Genentech) data or combination-therapy outcomes set the bar zovegalisib must clear in ReDiscover-2. Post-ASCO commentary from KOLs typically carries the stock ±10-15%.

🗓️ Jefferies Global Healthcare Conference — June 3, 2026 — Management fireside/1×1s; possible color on Phase 3 enrollment pace and next ReDiscover-2 data cut timing. Two days away.

🗓️ Goldman Sachs 47th Annual Global Healthcare Conference — June 8, 2026 — Same playbook as Jefferies. Both conferences are standard biotech catalyst venues where management guidance updates and interim data color can move mid-cap names 5-15%.

✅ NO earnings binary inside the window — Q2 2026 earnings expected early August 2026, AFTER the July 17 expiration. This is a tailwind for the short-put seller: theta is working for you and there is no overnight earnings gap risk inside the trade window.

📚 Recent Wins (Context for the Thesis)

✅ FDA Breakthrough Therapy Designation — February 3, 2026 — Major regulatory de-risking. FDA uses Breakthrough Designation sparingly; granting it to zovegalisib signals genuine unmet need and clinical data quality.

✅ ISSVA 2026 — 60% volumetric response in vascular anomalies (May 19, 2026) — Opens a rare-disease franchise separate from breast cancer. Two-indication story is worth meaningfully more than one.

✅ ESMO TAT 2026 — Phase 1/2 ReDiscover combination data (March 16, 2026) — Zovegalisib 400mg BID + fulvestrant well-tolerated across 60 patients, supporting the Phase 3 dose selection.

✅ $275M offering at $12/share completed May 19-20 — Dilution is in the rear-view mirror. RLAY now has ≈$917M total runway into 2029 per Q1 2026 results. The desk selling puts today is comfortable no fresh equity raise is needed near-term.

✅ Nextech Invest — 855,097 shares (≈$6.1M) accumulated Feb 2026 — Institutional conviction building before today's put-write.

RLY-4008 note: The FGFR2 inhibitor lirafugratinib was globally out-licensed to Elevar Therapeutics in December 2024 — Relay now collects milestones and royalties but is no longer driving development. It is not a near-term Relay-controlled catalyst.

---

🎲 Price Targets & Probabilities by July 17, 2026

Using gamma levels and the ±$6.67 implied move as our framework:

📈 Bull Case (35% probability)

Target: $15.00–$20.71

✅ ASCO/conference data flow confirms zovegalisib differentiation vs Inavolisib ✅ Jefferies or Goldman management color hints at strong Phase 3 enrollment pace ✅ Stock closes above $15 at expiry → put-write seller keeps the full $1.2M premium, zero assignment ✅ $15 gamma wall acts as magnet; analyst consensus target ≈$21-22 per TipRanks provides longer-term ceiling marker

🎯 Base Case (40% probability)

Target: $12.60–$15.00 (partial premium capture)

📊 Stock drifts between the $12.60 breakeven and the $15 strike — put seller makes a partial profit (premium collected minus assignment discount, or option decays as stock hovers) 📊 Conference season delivers qualitative color but no binary catalyst to spike through $15 in 6 weeks 📊 Theta works steadily in the put-writer's favor; IV slowly decays as no major event materializes

📉 Bear Case (25% probability)

Target: Below $12.60 (put seller starts losing)

😰 Competitive Inavolisib data at ASCO undercuts the zovegalisib differentiation narrative 😰 Small-cap biotech sector rotation or risk-off macro takes RLAY back toward the offering zone 😰 Any Phase 3 enrollment or safety signal turns negative during conference season 😰 Break below $12.60 = the put seller is "in the loss zone" (though still a paper loss until expiry) 😰 The implied move lower bound of $7.37 is the tail scenario — catastrophic clinical setback (≈2029 ReDiscover-2 topline is still 1-2 years away, so this is low probability inside 6 weeks)

---

💡 What This Trade Means for Four Types of Traders

🎰 YOLO Trader

Not for you on this specific structure. The STO earns a capped $1.2M max profit and risks ≈$6.3M in a catastrophic scenario. The juice-to-risk ratio doesn't suit a high-octane style. If you want RLAY exposure directionally, buying the $15 calls (the other side of this very trade) is the YOLO play — you're essentially betting alongside the put buyer who paid $1.2M to hedge or take a directional position against this writer.

📈 Swing Trader

This week has TWO near-term catalysts: Jefferies Healthcare Conference June 3 and Goldman Sachs Healthcare Conference June 8. Biotech conference management presentations routinely move mid-caps 8-15% on enrollment color or updated data framing. A swing position in RLAY common stock or short-dated calls (July $14 or $15 strike) into the conference week could capture a move toward that $15 gamma magnet. Keep position sizing modest — RLAY has ≈47% implied move through July 17, which means 5-8% daily swings on no news are normal.

💵 Premium Collector

Today's trade is your textbook. The desk wrote an ITM put (strike $15, spot $13.54) with 46 days to expiry and collected $2.40 (≈17.7% of spot) in a single print. The breakeven ($12.60) lands below the recent institutional offering clearing price ($12.00) — creating a "natural floor" anchor. No earnings binary inside the window. Rich IV (47.5% implied move) makes the premium attractive. If you run a cash-secured put strategy, RLAY July 17 $13 or $12.50 puts are a lower-strike, lower-risk version of the same theme — the desk just went more aggressive by writing the $15 ITM put.

🎓 Beginner — The Lesson Here

Here is the single most important thing to understand about this trade: selling a put is a BULLISH move, not a bearish one. When you sell a put, you are agreeing to buy the stock at the strike price if it falls there. You only do that if you think the stock is worth owning at that price. The put-writer here is saying "I want RLAY at $12.60 net — that is my price." Compare: the strike $15 is ABOVE current price $13.54, meaning the option is in-the-money, and the writer is being paid $2.40 to absorb that $1.46 gap. The $2.40 premium for a $15 put on a $13.54 stock means $1.46 is intrinsic value (the built-in ITM amount) and $0.94 is pure time value — the market's way of pricing uncertainty. Always check your current spot vs. the strike and breakeven before classifying a put-write as bullish or bearish. Spot above breakeven = put-writer currently in the money on the trade.

---

⚠️ Risk Factors

Don't ignore these:

🧬 Phase 3 clinical risk — ReDiscover-2 topline is not expected until 2027-2028. While there is no binary read inside the July 17 window, any interim safety signal, enrollment slowdown, or negative update during conference season could weigh heavily. Phase 3 failures in oncology remain the single largest risk for any biotech.

⚔️ Roche/Genentech Inavolisib (Itovebi) competition — Inavolisib is already FDA-approved in the same PIK3CA-mutant HR+/HER2- breast cancer indication. Zovegalisib must demonstrate clear differentiation in selectivity, tolerability, or durability. Any ASCO-window Inavolisib data updates that look compelling could pressure RLAY sentiment before the July 17 expiry.

💸 Dilution recency — The ≈23M new shares from the May offering represent ≈8% share-count dilution priced just 12 days ago. Digesting that issuance takes time; multi-expansion is limited until clinical re-rating begins.

📉 Small/mid-cap biotech beta — RLAY is a ≈$2.9B name with 47% implied volatility. Daily 5-10% moves on no news are entirely normal. The put-write seller can absorb that volatility because their breakeven ($12.60) is well below today's spot — but if sector rotation hits biotech hard (as it can in risk-off environments), the stock could test that level.

🔍 What the tape CANNOT prove — We know the print is an STO (5,000 new short puts written), the premium collected (≈$1.2M), and the structure. We do not know: the broker or counterparty, whether this is a standalone cash-secured put or part of a larger portfolio strategy, whether the put writer owns RLAY shares (covered) or is writing naked, or what their cost basis is on any underlying position. The OI confirmation tomorrow morning is the next objective checkpoint.

---

🎯 The Bottom Line

Here's the deal: A desk just crossed a $1.2M put-write on RLAY with a breakeven below the May institutional offering price. That is not an accident — it is a deliberate "I'll buy RLAY cheaper than the follow-on" thesis. With ≈$917M cash runway into 2029, an FDA Breakthrough Therapy-designated drug in Phase 3, a newly opened vascular-anomalies franchise, and analyst consensus pointing toward ≈$21-22 average targets (+55-65% upside), the setup has genuine merit.

Mark your calendar:

• 📅 Tuesday June 2, ≈06:30 ET — OI confirmation check (expect ≈5,010 on the $15 put)
• 📅 June 3 — Jefferies Global Healthcare Conference (near-term swing catalyst)
• 📅 June 8 — Goldman Sachs Global Healthcare Conference (enrollment/data color possible)
• 📅 June 2-15 — ASCO 2026 read-through window (PI3Kα competitive landscape re-set)
• 📅 July 17, 2026 — Put expiration; put-writer keeps full $1.2M if RLAY ≥ $15

If you own RLAY: The thesis remains intact. The put-write at $12.60 breakeven is a meaningful institutional signal that a desk views $12-13 as a reasonable accumulation zone, not a danger zone. The Jefferies/Goldman conferences this week are your near-term events to watch.

If you're on the sidelines: Conference week (June 3-8) is a reasonable entry window for a swing position. Use the $12.60 breakeven (and the $12.00 offering price just below it) as your mental stop reference — two institutional data points saying "this is where smart money sees value."

The fundamental lesson: Rich IV + no earnings binary + a Breakthrough Therapy story + a desk anchoring at a price below the most recent institutional offering = a clean short-put setup. It does not mean RLAY will rally. It means a sophisticated desk has concluded that $12.60 is a price they can live with owning this stock — and they got paid $1.2M to wait and see.

---

Disclaimer: Options trading involves substantial risk of loss and is not suitable for all investors. Selling puts carries the obligation to purchase shares at the strike price, which can result in significant losses if the stock declines materially. This analysis is for educational and informational purposes only and does not constitute financial advice. Always do your own research and consult a licensed financial advisor before trading. The trade described here is an institutional block cross — the strategy, position sizing, and risk tolerance of the counterparties may differ materially from a retail investor's situation. Past performance does not guarantee future results.

---

About Relay Therapeutics: Relay Therapeutics, Inc. (NASDAQ: RLAY) is a clinical-stage precision-medicine biotechnology company based in Cambridge, MA, developing small-molecule inhibitors using its proprietary Dynamo platform (motion-based protein dynamics). Market cap ≈$2.9B. Lead asset: zovegalisib (RLY-2608) for PIK3CA-mutant HR+/HER2- advanced breast cancer (FDA Breakthrough Therapy Designation, Phase 3 ReDiscover-2) and vascular anomalies.